Every day, physicians across the United States stop what they're doing—examining patients, reviewing charts, making clinical decisions—to fill out forms asking insurance companies for permission to deliver care they've already determined is necessary. This process, known as prior authorization, has become one of the most contentious friction points in American healthcare.

Insurers argue it's an essential safeguard against unnecessary spending, a rational mechanism for ensuring that expensive treatments and procedures meet evidence-based criteria before dollars flow. Physicians and patient advocates counter that it's a bureaucratic maze that delays critical care, drives up administrative costs, and quietly shifts medical decision-making from the exam room to the insurance office.

The truth, as with most policy debates, resists simple framing. Prior authorization sits at the intersection of cost control, clinical autonomy, and patient access—three priorities that don't always move in the same direction. Understanding how this mechanism actually works in practice, and what the evidence says about its effects, is essential for anyone trying to evaluate the reform proposals now gaining momentum across state legislatures and federal agencies.

Prior authorization emerged from a straightforward premise in managed care: not every service a provider orders is medically necessary, and a review process before delivery can prevent wasteful spending. Insurers apply these requirements selectively, targeting high-cost services like advanced imaging, specialty medications, elective surgeries, and certain medical devices where variation in utilization patterns suggests overuse or where lower-cost alternatives exist.

The mechanism operates through what policy analysts call utilization management—a set of tools designed to ensure that healthcare resources flow toward interventions supported by clinical evidence. In theory, prior authorization acts as a checkpoint, comparing a proposed service against established medical criteria before approving coverage. When it works as intended, it filters out low-value care without impeding access to treatments patients genuinely need.

From the insurer's perspective, the numbers support continued use. Industry data suggests that a meaningful percentage of prior authorization requests are either modified or denied, indicating that the process catches orders that don't meet coverage criteria. Health plans point to these denial rates as evidence that the system is performing its intended function—redirecting resources away from services that lack sufficient clinical justification.

But the rationale rests on a critical assumption: that the criteria being applied are genuinely evidence-based and consistently updated, and that the review process accurately distinguishes between necessary and unnecessary care. When those conditions aren't met—when criteria lag behind current evidence, when reviewers lack relevant clinical expertise, or when the process is applied too broadly—the gatekeeping function degrades. What was designed as a precision tool for cost control can become a blunt instrument that generates friction without proportionate value.

Takeaway

The strength of any gatekeeping mechanism depends entirely on the quality of its criteria and the precision of its application. A checkpoint that can't reliably distinguish necessary from unnecessary care isn't managing utilization—it's just managing paperwork.

The evidence on prior authorization's administrative costs is striking. The American Medical Association's surveys consistently find that physician practices spend an average of nearly two business days per week completing prior authorization requests. A 2022 study published in Health Affairs estimated that U.S. physicians and their staff spend approximately $34 billion annually on interactions with health plans, with prior authorization representing a substantial share. These aren't abstract numbers—they translate into exam rooms sitting empty, support staff diverted from patient care, and physicians burning hours on paperwork instead of clinical work.

The access implications are equally well-documented. Surveys of physicians across specialties report that prior authorization frequently delays necessary care, with significant percentages of practitioners reporting that patients have abandoned treatment due to authorization hurdles. In oncology, cardiology, and rheumatology—fields where treatment timing can directly affect outcomes—delays measured in days or weeks can carry real clinical consequences. The process doesn't just slow care down; in some cases, it effectively prevents it.

What makes the burden particularly difficult to justify is the approval rate. Studies consistently show that the vast majority of prior authorization requests—often exceeding 80 percent—are ultimately approved. This raises an uncomfortable question for defenders of the status quo: if four out of five requests pass review, is the system efficiently catching the problematic fifth, or is it primarily generating friction for the four that would have been appropriate all along?

The distributional effects also deserve scrutiny. Prior authorization burdens don't fall evenly. Smaller practices with fewer administrative resources are disproportionately affected. Patients with complex conditions requiring multiple authorizations face compounding delays. And research suggests that vulnerable populations—those with lower health literacy, less stable insurance coverage, or fewer resources to navigate appeals—are most likely to fall through the cracks when authorization creates barriers to access.

Takeaway

When a system approves the vast majority of what it reviews, the relevant question shifts from whether the filter catches bad claims to whether the cost of filtering—in money, time, and foregone care—exceeds the cost of what it catches.

Reform efforts are advancing on multiple fronts. At the federal level, the Centers for Medicare and Medicaid Services finalized a rule in 2024 requiring certain payers to implement electronic prior authorization systems and respond to standard requests within 72 hours for urgent care and seven days for non-urgent services. More than 30 states have enacted or introduced legislation imposing transparency requirements, response time limits, or gold card programs that exempt physicians with high approval rates from prior authorization requirements for specified periods.

Gold card provisions represent a particularly interesting policy design. Texas implemented one of the first statewide programs, automatically exempting providers whose prior authorization requests were approved at least 90 percent of the time. The logic is elegant: if a physician consistently orders care that meets insurer criteria, requiring ongoing case-by-case review generates cost without corresponding benefit. Early evidence from Texas suggests the program has reduced administrative burden for qualifying physicians without significant increases in inappropriate utilization.

Technology offers another pathway. Electronic prior authorization—often called ePA—integrates the review process directly into electronic health record workflows, automating data submission and enabling real-time or near-real-time determinations for straightforward cases. Industry pilots have demonstrated that automation can cut processing times from days to minutes for requests that meet clear-cut criteria, reserving human review for genuinely complex or ambiguous cases where clinical judgment adds value.

The challenge for policymakers is calibrating reform. Eliminating prior authorization entirely risks removing a lever—however imperfect—for managing utilization in a system that still struggles with overuse of certain services. But the current implementation has drifted far from its original purpose, creating costs that in many cases exceed the savings it generates. The most promising reforms share a common principle: preserve review where it adds clinical value, and remove it where it merely adds friction. Getting that distinction right is the policy challenge of the moment.

Takeaway

The best reforms don't simply loosen or tighten a policy mechanism—they redesign it to concentrate scrutiny where it matters and eliminate it where it doesn't. Precision in policy design is as important as precision in clinical care.

Prior authorization is neither purely a necessary safeguard nor purely an administrative obstruction. It's a policy tool that has expanded well beyond the conditions under which it performs well—applied too broadly, reviewed too slowly, and updated too infrequently to consistently serve its stated purpose.

The reform momentum is real and, on the evidence, overdue. Gold card exemptions, electronic automation, and mandated response timelines each address a different dimension of the problem. Together, they point toward a system where utilization review is more targeted, faster, and less burdensome for the cases that don't warrant it.

The broader lesson extends beyond prior authorization itself: any oversight mechanism must be regularly evaluated not just for whether it catches problems, but for what it costs everyone it doesn't catch. Accountability should run in both directions.